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There is an imperative need for effective preventive vaccines against human cyto-
megalovirus as it poses a significant threat to the immunologically immature, causing 
congenital disease, and to the immune compromised including transplant recipients. 
In this study, we examined the efficacy of synthetic long peptides (SLPs) as a CD4+ 
and CD8+ T cell-eliciting preventive vaccine approach against mouse CMV (MCMV) 
infection. In addition, the use of agonistic OX40 antibodies to enhance vaccine efficacy 
was explored. Immunocompetent C57BL/6 mice were vaccinated in a prime-boost vac-
cination regiment with SLPs comprising various MHC class I- and II-restricted peptide 
epitopes of MCMV-encoded antigens. Enforced OX40 stimulation resulted in superior 
MCMV-specific CD4+ as CD8+ T cell responses when applied during booster SLP vac-
cination. Vaccination with a mixture of SLPs containing MHC class II epitopes and OX40 
agonistic antibodies resulted in a moderate reduction of the viral titers after challenge 
with lytic MCMV infection. Markedly, the combination of SLP vaccines containing both 
MHC class I and II epitopes plus OX40 activation during booster vaccination resulted in 
polyfunctional (i.e., IFN-γ+, TNF+, IL-2+) CD4+ and CD8+ T cell responses that were even 
higher in magnitude when compared to those induced by the virus, and this resulted 
in the best containment of virus dissemination. Our results show that the induction of 
strong T cell responses can be a fundamental component in the design of vaccines 
against persistent viral infections.
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inTrODUcTiOn
It is estimated that 60–80% of people worldwide are infected by the prototypic β-herpesvirus human 
cytomegalovirus (HCMV). CMV establishes low-level viral persistence within immunocompetent 
hosts without clinical symptoms. However, it can cause life-threatening disease in the immuno-
logical immature (unborn babies and newborns) and immunocompromised individuals (e.g., bone 
marrow and organ transplant recipients) (1, 2). Although new antiviral drugs against CMV are in 
clinical development, the most commonly used agents display toxicity. Importantly, no licensed 
prophylactic or therapeutic vaccines exist for CMV at present. Consequently, there is an imperative 
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need to identify potent vaccine modalities to prevent HCMV 
infection (3–5).
CD4+ and CD8+ T cell responses play a critical role in 
controlling CMV infection in both mouse and human. While 
CD4+ T cells seem to be more crucial in the early phase after 
infection, CD8+ T cells are imperative during latency and 
harbor superior protective properties upon rechallenge (6–9). 
Moreover, adoptive transfer approaches established the pivotal 
role of CMV-specific CD4+ and CD8+ T cells in orchestrating 
virus replication control (10–12). During CMV infection, 
CD4+ and CD8+ T cell responses either follow the traditional 
course comprised by massive expansion followed by rapid 
contraction and maintenance at low levels or instead do not 
undergo contraction but remain at high frequency or even 
expand gradually. The latter has been described as memory 
T cell inflation and has been observed for a restricted set of 
immunodominant CMV antigens (13–16). Memory inflation 
is thought to occur due to low-level persistent antigenic prim-
ing and requires certain costimulatory receptor-ligand pairs 
of which CD27–CD70 and OX40–OX40L interactions are 
important (17, 18). Phenotypically inflationary T cells exhibit 
effector-like properties without signs of exhaustion (14, 16, 
19). The comparable nature of the T cell response to mouse 
CMV (MCMV) and HCMV is also found for B cell and NK cell 
responses and is likely related to the similarities of both viruses 
in tropism, pathology, and the establishment of latent infection 
that reactivates upon immunosuppression (20, 21).
Recently, we demonstrated that synthetic long peptide (SLP) 
vaccines, designed to exclusively induce MHC class I-restricted 
CD8+ T cells, were able to elicit robust and polyfunctional T cell 
responses that led to reduced MCMV replication in C57BL/6 
and BALB/c mouse strains after challenge (22). However, live 
MCMV vaccines were more efficient which prompted us to fur-
ther improve the SLP vaccine efficacy. Since CD4+ helper T cells 
promote long-term maintenance of memory CD8+ T cells, also 
during MCMV infection (23, 24), and display direct antiviral 
capabilities (12, 25), the induction of CD4+ T cells may improve 
the efficacy of the SLP vaccine. Here, we analyzed the potency 
of SLP vaccines inducing MCMV-specific CD4+ T cells, either 
alone or in conjunction with SLPs eliciting MCMV-specific 
CD8+ T cells. Enforced OX40 signaling was used to enhance the 
expansion of both CD4+ and CD8+ T cell subsets. We show that 
combined administration of SLPs eliciting CD4+ and CD8+ T 
cells and OX40 stimulation during booster vaccination leads to 
a startling increase of both the T cell magnitude and polyfunc-
tionality, ultimately leading to efficient control of lytic MCMV 
infection.
aniMals anD MeThODs
Mice
Wild-type female C57BL/6 mice (8–10  weeks) were purchased 
from Charles River Laboratories (L’Arbresle, France) and Ly5.1 
(SJL; CD45.1) congenic mice on a C57BL/6 genetic background 
were obtained from The Jackson Laboratory. Mice were bred and 
housed under specific-pathogen-free conditions at the Central 
Animal Facility of Leiden University Medical Center (LUMC). 
Experimental procedures were approved by the LUMC Animal 
Experiments Ethical Committee and conducted according to the 
Dutch Experiments on Animals Act and the Council of Europe 
(#13156 and #14187).
Viral infections
Virus stocks were prepared from salivary glands of BALB/c 
mice infected with MCMV-Smith [American Type Culture 
Collection (ATCC)]. The viral titers of the produced virus stocks 
were determined by viral plaque assays with mouse NIH-3T3 
Embryonic Fibroblasts (ATCC). C57BL/6 mice were infected 
intraperitoneally (i.p.) with 5 ×  104 PFU MCMV in 400  µl of 
PBS. 60 days post-booster vaccination or infection, mice were 
rechallenged with 5 ×  104 PFU MCMV. Viral loads in spleen, 
liver, and lungs were determined by real-time PCR at day 5 post 
challenge as described previously (26). Due to differences in 
peak viral replication, the viral load in the salivary glands was 
not measured.
Peptides and Vaccination
Short (9–10 aa) and long (20–21 aa) peptides containing MHC 
class I-restricted T cell epitopes (22) and 15 aa long peptides 
containing MHC class II epitopes (15) were produced at the 
GMP-peptide facility of the LUMC. The purity (75–90%) of the 
synthesized peptides was determined by HPLC and the molecu-
lar weight by mass spectrometry. All peptide sequences used in 
this study are listed and described in Table S1 in Supplementary 
Material. Both single and mixed SLP vaccines were administered 
subcutaneously (s.c.) at the tail base by delivery of 50 µg of each 
SLP and 20 µg CpG (ODN 1826, InvivoGen) in a total volume 
of 50  µl in PBS. Booster SLP vaccinations were provided after 
2  weeks. At the indicated times (during prime and/or booster 
vaccination), mice were injected i.p. with 150 µg agonistic OX40 
mAb (clone OX86) dissolved in 150 µl of PBS. All SLP vaccine 
administrations were well tolerated without adverse events and 
signs of hypersensitivity.
Flow cytometry
To evaluate CD4+ and CD8+ T cell responses, cell surface 
and intracellular cytokine staining in splenocytes and blood 
lymphocytes were performed as previously described (27). In 
brief, to determine the cytokine production capacity, single-cell 
suspensions from spleens were stimulated with short MHC 
class I peptides (2 µg/ml) for 5 h in the presence of brefeldin A 
(Golgiplug; BD Pharmingen) or with long MHC class II peptides 
(5 µg/ml) for 8 h of which the last 6 h in presence of brefeldin 
A. MHC class I tetramers specific for the M45985–993, M57816–824, 
m139419–426, M38316–323, and IE3416–423 MCMV epitopes were 
used. Fluorochrome-conjugated mAbs were obtained from BD 
Biosciences, Biolegend, or eBioscience. Flow cytometry gating 
strategies are shown in Figure S6 in Supplementary Material. All 
data were acquired on a LSRFortessa cytometer (BD Biosciences) 
and analyzed with FlowJo-V10 software (Tree Star).
antibody Detection by elisa
Total IgG, IgG2b, IgG2c, IgG3, IgE, and IgA concentrations 
were determined by ELISA in serum samples as previously 
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described (26). Briefly, Nunc-Immuno Maxisorp plates (Fisher 
Scientific) were coated overnight with 2 µg/ml MHC class II SLPs 
in bicarbonate buffer, and after blocking (skim milk powder, 
Fluka BioChemika) sera from mice (i) chronically infected, (ii) 
long term vaccinated with MHC class II SLP vaccines and anti-
OX40 mAb treated (i.p. during booster vaccination only), or (iii) 
uninfected were added. Next, plates were incubated with various 
HRP-conjugated antibodies (SouthernBiotech) to detect differ-
ent immunoglobulin isotypes. Plates were developed with TMB 
substrate (Sigma Aldrich), and the color reaction was stopped 
by the addition of 1 M H2SO4. To serve as a positive control, a 
peptide from the M2 protein (eM2) of influenza A virus with 
known ability to induce antibodies and corresponding serum 
was used. Optical density was read at 450 nm (OD450) using a 
Microplate reader (Model 680, Bio-Rad).
adoptive T cell Transfers
The secondary expansion potential of the SLP vaccine-induced 
antigen-specific CD8+ T cells receiving agonistic OX40 mAb 
only during booster vaccination was determined by adoptive 
transfers. Splenic memory (day 65) CD8+ T cells from SLP vac-
cinated CD45.1+ congenic mice were negatively enriched with 
magnetic sorting using the CD8+ T cell isolation kit (Miltenyi 
Biotec). 2 × 106 total CD8+ T cells were retro-orbitally injected 
(in a total volume of 200 µl in PBS) into naive CD45.2+ recipients. 
Recipient mice were rested for 2 h and concomitantly infected 
with 5 × 104 PFU MCMV. Subsequently, in order to quantify the 
number of the vaccine antigen-specific CD8+ T cells that was 
transferred, a representative amount of cells was stained with 
MHC class I tetramers and with fluorochrome labeled antibodies 
against CD44, CD3, CD4, and CD8. The number of the donor’s 
vaccine-specific T cells transferred was ranging between 8 × 103 
and 2.5 × 104 cells for the group that did not receive OX40 mAb 
and between 1.8 ×  104 and 4.5 ×  104 cells for the OX40 mAb 
boosted group. 6 days later, the number of vaccine-specific CD8+ 
T cells of the donor was measured (based on the expression of 
the CD45.1 marker) by flow cytometry, and the fold expansion 
was calculated.
statistical analyses
Statistics were calculated using the unpaired Student’s t-test or 
ANOVA in GraphPad Prism software (GraphPad Software Inc., 
USA). *P < 00.5, **P < 0.01, ***P < 0.001, and ****P < 0.00001.
resUlTs
Prime/Boost Vaccination with slPs 
inducing McMV-specific cD4+ T cell 
responses
MHC class II epitopes from MCMV-encoded proteins have 
previously been identified by us in the C57BL/6 mouse strain 
(MHC haplotype H-2b) (15), and five immunogenic epitopes (i.e., 
m18872–886, M25409–423, m139560–574, m14224–38, and m09133–147) were 
selected for the SLP vaccine platform (Table S1 in Supplementary 
Material). Initially, the potential of single SLP-based vaccines in 
eliciting CD4+ T cell responses was assessed in a prime/boost 
vaccination setting (2 weeks apart) with the TLR9 ligand CpG 
as adjuvant. At day 8 after the first SLP vaccination, CD4+ T 
cell responses were not detected by polychromatic intracellular 
cytokine staining (data not shown) but they became detectable in 
the spleen at day 8 after the booster SLP vaccination (Figure 1A). 
However, these responses were relatively low when compared to 
SLP-induced CD8+ T cell responses (22). Analysis of the cytokine 
profile revealed the presence of single IFN-γ, double IFN-γ/TNF, 
and triple IFN-γ/TNF/IL-2 cytokine-producing CD4+ T cell 
populations (Figure 1B).
For clinical applications multiple SLPs need to be combined 
in order to deal with MHC heterogeneity. Moreover, the breadth 
of SLP vaccines is important for the efficacy (22). Hence, mice 
were vaccinated with a mixture of the five SLPs, and the CD4+ 
T cell response for each individual peptide epitope was meas-
ured. CD4+ T cell reactivity to all MHC class II epitopes was 
detected (Figure 1C), albeit that the response to each individual 
peptide was lower when compared to single SLP vaccination, 
suggesting that competition among CD4+ T cell peptide epitopes 
occurs in multivalent vaccines. Moreover, in comparison to the 
CD4+ T  cell response observed after MCMV infection, vac-
cination with a mixture of MHC class II SLPs resulted in lower 
numbers of MCMV-specific T cells (Figure 1C). Nevertheless, 
the cytokine polyfunctionality of the SLP-elicited CD4+ T cells 
was augmented compared to MCMV-induced CD4+ T cells 
(Figure  1D). Taken together, these results show that prime/
boost vaccination with a mixture of MHC class II epitope-
containing SLPs elicits polyfunctional MCMV-specific CD4+ 
T cell responses, but in magnitude these are lower as compared 
to those induced by the virus itself.
enforced OX40 Triggering during Booster 
Vaccination shows superior induction of 
slP-elicited cD4+ T cell responses
Next, we attempted to augment the magnitude of the SLP-
induced CD4+ T cell responses. As OX40-mediated signals are 
important for enhancing CD4+ T cell expansion and survival 
(28), we decided to use an agonistic OX40 antibody that 
provides in  vivo OX40 stimulation. First, we investigated the 
scheduling of the agonistic OX40 antibody administration (i.e., 
during priming only, during booster only or during priming 
and booster) in order to obtain the most optimal CD4+ T 
cell stimulation (Figure  2A). The magnitude of the T cell 
response elicited by the SLP containing the M25409–423 epitope 
was measured 8  days post-booster vaccination in the spleen. 
OX40 stimulation clearly increased the magnitude of the 
M25409–423-specific CD4+ T cell responses, and remarkably, this 
was most prominent when the mice received agonistic OX40 
antibody during the booster vaccination only (Figures 2B,C). 
Markedly, a >100-fold increase in IFN-γ+ CD4+ T cells was 
observed when compared to SLP vaccination without enforced 
OX40 stimulation, whereas the response was 17-fold and 
5-fold higher than in mice receiving OX40 antibody during 
priming only or during both priming and booster vaccination, 
respectively (Figure 2C). In addition, there was a striking gain 
in cytokine polyfunctionality when agonistic OX40 antibody 
FigUre 1 | Prime-boost synthetic long peptide (slP) vaccination with combined Mhc class ii slPs provokes the induction of strong and 
polyfunctional cD4+ T cell responses. (a) At day 8 post-booster vaccination with single SLPs containing MHC class II epitopes, the magnitude of the CD4+ T 
cell responses specific to the indicated epitopes was determined by intracellular cytokine staining after restimulation with peptide. Representative plots show 
percentages of IFN-γ versus TNF cytokine production of the vaccine-elicited CD4+ T cells. (B) Pie charts depict the percentages of the single (IFN-γ), double (IFN-γ/
TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD4+ T cell population at day 8 post-booster vaccination with single MHC class II 
SLPs. (c) Percentages (left) and total numbers (right) of splenic SLP and MCMV-specific IFN-γ+ CD4+ T cells at day 8 post-booster vaccination with a mixture of all 
five MHC class II SLPs are shown. (D) Pie charts depict the percentages of the single (IFN-γ), double (IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of 
each antigen-specific CD4+ T cell population at day 8 after booster vaccination with a mixture of all five MHC class II SLPs. Data represent mean values and are 
representative of three independent experiments (n = 4–5 per group). *P < 0.05; **P < 0.01; ns, not significant.
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FigUre 2 | activation of the OX40 axis during booster vaccination with a single Mhc class ii synthetic long peptide (slP) vaccine propels increment 
of the vaccine-induced cD4+ T cell response. (a) Scheme of the experimental procedure and the vaccination timeline. Wild-type C57BL/6 mice were 
vaccinated (i) s.c. with M25409–423 MHC class II SLP alone or (ii) with M25409–423 MHC class II SLP (s.c.) along with anti-OX40 mAb (i.p.). Two weeks after prime 
vaccination mice from group (i) and (ii) were divided into two groups, respectively, and a booster immunization was administered. Half mice received only the 
M25409–423 SLP and the other half were injected anti-OX40 mAb in addition to the M25409–423 SLP. (B) The total size of the splenic M25409–423 SLP vaccine-induced 
CD4+ T cells from each group was measured by intracellular cytokine staining. Representative plots depict percentages of IFN-γ versus TNF cytokine producing 
CD4+ T cell populations at day 8 post-booster vaccination. (c) Total numbers of splenic IFN-γ+ producing M25409–423 antigen-specific CD4+ T cells at day 8 post 
booster SLP vaccination and differential anti-OX40 mAb treatment are shown. (D) Total double (IFN-γ/TNF) and (e) triple (IFN-γ/TNF/IL-2) cytokine producers of 
M25409–423 vaccine-specific CD4+ T cells measured in spleen at day 8 post-booster vaccination. Fold differences among each population are also depicted (F). Pie 
charts show the percentages of the single (IFN-γ), double (IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of each M25409–423-specific CD4+ T cell 
population upon vaccination with M25409–423 SLP and anti-OX40 mAb. Data represent mean values and are representative of three independent experiments 
(n = 5–6 per group). *P < 0.05; **P < 0.01; ns, not significant.
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was provided during booster vaccination only (Figures 2D–F). 
Compared to SLP vaccination, the increase in absolute num-
bers of triple IFN-γ/TNF/IL-2 producers was even >200-fold 
(Figure  2E).
Next, we examined whether the strong increase in MCMV-
specific CD4+ T cells by administration of agonistic OX40 
antibody during booster vaccination was also evident in case 
of a mixture of SLPs. Clearly, at day 8 post-booster vaccination, 
a strong increase in both percentages and absolute numbers of 
the peptide-specific IFN-γ+ CD4+ T cells was observed for all 
epitopes in the mixture (Figure 3A). In addition, administration 
of OX40 antibody dramatically improved the cytokine polyfunc-
tional traits (Figure  3B). Most profoundly, OX40 stimulation 
augmented the IL-2 production capacity of the vaccine-induced 
CD4+ T cells (Figures 3B,C). Together, these results demonstrate 
that activation of the OX40 axis during booster SLP vaccination 
leads to superior CD4+ T cell expansion and induction of cytokine 
polyfunctionality.
Having established a powerful means to augment SLP vac-
cines containing MHC class II epitopes, we tested if the used 
SLPs may comprise unidentified class I epitopes and/or linear 
B cell epitopes leading to CD8+ T cells and antibody responses, 
respectively. However, intracellular cytokine staining did not 
reveal any induction of MCMV-specific CD8+ T cells and 
SLP-specific antibody ELISAs were negative (Figures S1A,B in 
Supplementary Material). Furthermore, increased percentages 
of activated NK cells were also not detected after SLP vaccina-
tion (Figure S1C in Supplementary Material), indicating that the 
intended MHC class II epitope-containing SLPs with enforced 
OX40 stimulation exclusively activate antigen-specific CD4+ 
T cell responses.
Provision of OX40 stimulation during 
Booster Vaccination also advances  
slP-induced cD8+ T cell responses
To improve our previously reported CD8+ T cell eliciting SLP 
vaccine modality (22), we here envisaged to combine both 
MHC class I and II epitope-containing SLPs. We, therefore, 
also analyzed the impact of OX40 engagement on vaccine-
induced CD8+ T cells in a similar scheduling experiment using 
a SLP exclusively containing the CD8+ T cell peptide epitope 
M57816–824 (Figure S2A in Supplementary Material). Consistent 
with the results described for CD4+ T cells, mice that were 
vaccinated and treated with agonistic OX40 antibody during 
booster vaccination displayed the strongest SLP-induced CD8+ 
T cell response in both blood and spleen (Figures S2B–F in 
Supplementary Material). The number of SLP-induced CD8+ 
T cells, determined either by IFN-γ reactivity or by MHC class 
I tetramer binding, at the peak after the boost were similar, indi-
cating that OX40 stimulation during SLP vaccination (provided 
either during priming, during booster or during prime/boost) 
induces functional (non-exhausted) CD8+ T cells (Figures S2C,D 
in Supplementary Material). The cell-surface phenotype based 
on KLRG1 and CD127 of the vaccine-induced CD8+ T cells 
at the peak of the response after the booster was comparable 
(Figure S2G in Supplementary Material).
Next, the impact of OX40 stimulation during booster 
 vaccination was evaluated for a mixture of MHC class I epitope-
containing SLPs. Longitudinal analysis of the SLP-specific 
CD8+ T cell response revealed that OX40 stimulation during 
booster vaccination clearly amplifies the expansion of all SLP 
vaccine-induced CD8+ T cells measured in blood and spleen 
(Figures 4A,B), although this effect was relatively lower when 
compared to that seen for CD4+ T cells. At the peak of the 
response, 8  days after booster SLP vaccination, the magnitude 
of the IFN-γ+CD8+ T cell response specific for each MHC class 
I-restricted epitope was again proportional to the MHC class 
I tetramer response (data not shown). However, the polyfunc-
tional cytokine profile was improved upon OX40 stimulation 
(Figures 4C,D). In particular, OX40 stimulation augmented the 
percentages and absolute number of the triple cytokine produc-
ers (Figures 4C,D).
To gain insight into the mechanisms underlying the appar-
ent impact of OX40 stimulation during booster vaccination, we 
examined the expression of the pro-apoptotic protein BCL-2, a 
known target of OX40 triggering and implicated in T cell survival 
(29). BCL-2 expression was upregulated by the vaccine-specific 
CD8+ T cells when OX40 stimulation was provided during booster 
vaccination compared to no OX40 stimulation (Figure  4E). 
Moreover, when agonistic OX40 antibody was administered dur-
ing both primary and booster vaccination, BCL-2 expression was 
downregulated. These results indicate that stimulation of OX40 
can bolster vaccine-induced CD8+ T cell expansion through a 
BCL-2-dependent mechanism, if this stimulation is correctly 
scheduled.
Over time, the SLP-induced CD8+ T cell responses contracted, 
yet the OX40 boosted epitope-specific CD8+ T cell responses to 
M38, M45, and M57 were maintained at higher levels (Figure 5A). 
At the memory phase (60 days after booster vaccination), there 
were higher percentages and numbers of triple (IFN-γ/TNF/IL-2) 
cytokine-producing vaccine-induced CD8+ T cells in mice that 
received agonistic OX40 antibody during booster vaccination 
(except for m139419–426) (Figures 5B,C).
We also tested the impact of the in  vivo OX40 stimulation 
on the secondary expansion potential, a hallmark of memory 
T cells. We performed adoptive transfer experiments in which 
congenically marked (CD45.1+) memory CD8+ T cells from 
SLP vaccinated mice were isolated and transferred into naïve 
recipient mice, which were subsequently challenged with 
MCMV (Figure S3A in Supplementary Material). Overall, the 
SLP-induced memory CD8+ T cells isolated from mice that also 
received OX40 stimulation during booster vaccination expanded 
better compared to the vaccine only group (Figures S3B,C in 
Supplementary Material).
Subsequently, we examined whether OX40 stimulation is able 
to further improve the prophylactic efficacy of the combined 
MHC class I SLP vaccine. At day 60, post-booster vaccination, 
mice were virally challenged and the titers were quantified in 
spleen, liver, and lungs. Similar to our previous study (22), vac-
cination with a mixture of MHC class I SLPs resulted in reduction 
of the virus titers (Figure 5D). Mice that received OX40 stimula-
tion during the booster showed increased potency to control the 
virus compared to mice that received no extra stimulation of 
FigUre 3 | OX40 activation during booster vaccination with combinatorial Mhc class ii synthetic long peptide (slP) vaccines leads to the induction 
of robust and polyfunctional cD4+ T cell responses. (a) Percentages (left) and total numbers (right) of the splenic epitope-specific IFN-γ+ CD4+ T cell responses 
elicited at day 8 post-booster vaccination with a mixture of SLPs containing MHC class II epitopes alone (CD4 SLP mixture; white bars) or with SLPs containing 
MHC class II epitopes and anti-OX40 mAb (CD4 SLP mixture + anti-OX40 boost; black bars). (B) Pie charts show the percentages of the single (IFN-γ), double 
(IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD4+ T cell population at day 8 post-booster vaccination with a mixture of MHC 
class II SLPs alone or with MHC class II SLPs plus anti-OX40 mAb. (c) Total triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD4+ T cell 
population were measured in spleen at day 8 post-booster vaccination with a mixture of MHC class II SLPs and anti-OX40 mAb or with SLPs alone. Fold difference 
is indicated. Data represent mean values and are representative of three independent experiments (n = 6 per group). *P < 0.05; **P < 0.01.
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OX40 (Figure 5D). All together, these data suggest that enforced 
OX40 stimulation during booster SLP vaccination does not only 
impact the expansion of activated CD8+ T cells but also has a 
long-lasting constructive influence on the magnitude and the 
functional profile of the vaccine-elicited CD8+ T cells leading to 
more effective viral control.
slP Vaccines inducing Both cD4+ and 
cD8+ T cells confer superior Protection 
against McMV infection
To evaluate if the provision of CD4+ T cells would benefit the 
CD8+ T cell response, C57BL/6 mice were vaccinated with a 
FigUre 4 | OX40 ligation during booster vaccination with a mixture of Mhc class i epitope-containing synthetic long peptides (slPs) leads to the 
induction of strong and polyfunctional cD8+ T cell responses. (a) Longitudinal analysis of the epitope-specific CD8+ T cell responses in blood induced by 
combinatorial MHC class I epitope-containing SLP vaccines without (CD8 SLP mixture) and with anti-OX40 mAb administration (given only during booster 
vaccination) (CD8 SLP mixture + a-OX40 boost). Data represent mean values ± SEM (n = 12 per group). (B) Total IFN-γ+ cytokine-producing CD8+ T cells for each 
antigen-specific population detected in spleen at day 8 post-booster vaccination with CD8 SLP mixture (white bars) or with CD8 SLP mixture + anti-OX40 boost 
(black bars). (c) Pie charts show the percentages of the single (IFN-γ), double (IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2)-specific cytokine producers of the antigen-
specific CD8+ T cell populations at day 8 post-booster vaccination. (D) Total numbers of IFN-γ/TNF/L-2 cytokine producing CD8+ T cells for each antigen-specific 
population detected in spleen at day 8 post-booster vaccination. (e) At day 8 after booster vaccination with combined MHC class I SLPs and/or anti-OX40 mAb 
(during booster or during both prime/boost), the BCL-2 protein expression was measured within the antigen-specific CD8+ T cells in spleen by flow cytometry. Fold 
changes between groups are depicted. Data represent mean values + SEM (n = 6 mice per group) and are representative of three independent experiments. 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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FigUre 5 | continued
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mixture of either all 5 MHC class I epitope-containing SLPs or 
with a mixture of all 5 MHC class I and all 5 class II epitope-
containing SLPs (Table 1 in Supplementary Material). Agonistic 
OX40 mAb was provided during the boost only. The CD8+ T cell 
response after the prime vaccination was higher when the SLP 
vaccine contained a mixture of MHC class I and II peptide 
FigUre 5 | continued 
agonistic OX40 mab administration during booster vaccination leads to improved memory synthetic long peptide (slP)-elicited cD8+ T cell 
responses. (a) Total single IFN-γ+ cytokine-producing CD8+ T cells for each antigen-specific population detected in spleen at day 60 post-booster vaccination 
with combinatorial MHC class I SLPs and anti-OX40 mAb (provided during booster vaccination) (CD8 SLP mixture + anti-OX40 boost) or with MHC class I SLPs 
alone (CD8 SLP mixture). Fold changes between groups are depicted. Data represent mean values + SEM (n = 6 per group). (B) Pie charts show the percentages 
of the single (IFN-γ), double (IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of each antigen-specific CD8+ T cell population in spleen at day 60 
post-booster vaccination with a mixture of MHC class I SLPs and anti-OX40 mAb (administered only during booster vaccination) or with MHC class I SLPs alone. 
(c) Total triple IFN-γ+/TNF+/IL-2+-producing CD8+ T cells for each antigen-specific population detected in spleen at day 60 post-booster vaccination. Fold 
changes between groups are depicted. Data represent mean values + SEM (n = 6 per group). (D) Different groups of mice [unvaccinated (naive), mouse CMV 
(MCMV) infected (live-virus vaccine), vaccinated with a mixture of all 5 MHC class I SLPs, vaccinated with a mixture of all five MHC class I SLPs and anti-OX40 
mAb (given only during booster vaccination), or treated with a-OX40 mAb only] were challenged at day 60 postvaccination/infection with 5 × 104 PFU salivary 
gland-derived MCMV Smith. At day 5, post challenge spleen, liver, and lungs were harvested and the viral genome copies were determined by qPCR. The viral 
titers of individual mice are depicted (n = 5–8 mice per group). Mean ± SEM is indicated. The detection limit was below 1,000 genome copies as measured in 
naive mice. Experiments were performed twice with similar outcome. *P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant as compared to the unvaccinated 
group unless otherwise indicated.
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epitopes (Figure  6A; Figure S4A in Supplementary Material), 
stressing the importance of CD4+ T cell help during the prim-
ing. Also, the phenotype of the vaccine-induced CD8+ T cells 
after prime vaccination revealed slightly more effector-type 
(KLRG-1+CD127-) CD8+ T cells when CD4+ T cell help was 
provided (Figure S4B Supplementary Material), whereas the 
polyfunctionality of the vaccine-induced CD8+ T cells remained 
unchanged (data not shown). However, at day 7/8 after booster 
SLP vaccination, the effect of CD4+ T cell help on the magnitude 
of the vaccine-induced CD8+ T cell response was no longer 
detectable in blood (Figure  6A) and spleen (Figure  6B). At 
this time-point, also no difference in the CD8+ T cell cytokine 
polyfunctionality and phenotype was found (Figures  6C,D). 
Furthermore, the size and polyfunctionality of the CD4+ T 
cells responses induced at the peak response after combined 
MHC class I and II SLP vaccination was similar to vaccination 
with MHC class II SLPs only (Figures S5A,B in Supplementary 
Material). Taken together, vaccination with a mixture of MHC 
class I and II epitope-containing SLPs resulted in enhanced pri-
mary CD8+ T cell expansion compared to vaccination with class 
I epitope-containing SLPs only, but no additional effects of the 
helper T cells were observed after the enforced OX40 stimulation 
provided during booster vaccination.
Ultimately, we analyzed the prophylactic efficacy of the 
SLP-induced MCMV-specific CD4+ and CD8+ T cells to control 
viral replication. At day 60 post-booster SLP vaccination, mice 
were infected with MCMV and 5 days later the viral titers were 
quantified. The viral load of unvaccinated (naive) mice chal-
lenged with MCMV was found significantly higher in spleen, 
liver, and lungs compared to the viral load of mice that received 
earlier a virulent virus as a vaccine. This result suggests that 
pre-existing immunity to MCMV can inhibit virus replication 
during subsequent infection (Figure 7). Furthermore, the viral 
titers of mice that had received the virulent virus-based vaccine 
were similar to those measured during chronic MCMV infec-
tion, indicating that this is the maximum of immune control 
that can be achieved. Mice vaccinated with the mixture of SLPs 
containing MHC class II epitopes plus OX40 triggering during 
booster vaccination displayed significant reduction in viral 
load in all tested organs (Figure  7), indicating that the SLP-
induced MCMV-specific CD4+ T cells display direct antiviral 
properties. Vaccination with the mixture of MHC class I SLPs 
plus anti-OX40 during booster resulted in a more efficient 
reduction of viral load in all organs. Strikingly, mice that 
received a mixture of MHC class I and II epitope-containing 
SLPs and OX40 stimulation during booster vaccination dis-
played the strongest reduction in viral load (Figure 7). Notably, 
the SLP vaccine-induced reduction in viral load in the spleen 
and liver was almost as effective as to what is observed after 
vaccination with virulent virus. Thus, SLP vaccines comprising 
a mixture of MHC class I and II SLPs has the highest protec-
tion potency compared to similar vaccines that elicit merely 
MCMV-specific CD4+ or CD8+ T cell responses. All together, 
we conclude that OX40 activation during booster vaccination 
empowers SLP-induced memory CD4+ and CD8+ T cells to 
efficiently counteract lytic MCMV infection.
DiscUssiOn
In this study, we show that SLP-based vaccine strategies elicit-
ing vigorous polyfunctional CD4+ and CD8+ T cell responses 
are highly effective against MCMV infection. While SLP-based 
vaccines that evoke solely CD8+ T cell responses display already 
efficacy against lytic MCMV infection (22), vaccination with a 
mixture of various immunodominant MHC class II and MHC 
class I MCMV epitopes and the combination with enforced 
OX40 stimulation results in superior vaccine efficacy. Former 
explored CMV vaccines focused mainly on the induction of 
neutralizing antibodies and thus far did not show substantial 
efficacy (3–5). Our finding that SLP-based vaccines that 
merely provoke CD4+ and CD8+ T cell responses are almost as 
efficient as a virulent vaccine suggests that the inclusion of T 
cell-stimulating antigens should facilitate the design of more 
efficient vaccines against CMV.
Signals through the OX40 costimulatory receptor are known 
to regulate expansion and survival of both CD4+ and CD8+ 
T  cells after antigen encounter (28, 30). Consistent with this, 
OX40 had a robust effect on the magnitude of the effector SLP 
vaccine-induced CD4+ and CD8+ T cells and on their capacity 
to induce “Th1” cytokine responses (especially IL-2). This effect 
of OX40 costimulatory signals was stronger when agonistic 
antibody to OX40 was provided during booster SLP vaccination. 
FigUre 6 | combination of Mhc class i and ii epitope-containing synthetic long peptide (slP) vaccines and OX40 agonistic mab during booster 
vaccination leads to robust induction of both cD4+ and cD8+ T cell responses. C57BL/6 mice were vaccinated s.c. with a combination of all MHC class I 
epitope-containing SLPs (CD8 SLP) or with a combination of all MHC class I and II epitope-containing SLPs (CD4 + CD8 SLP). In both groups agonistic OX40 
mAb was administered i.p. during booster vaccination. (a) Kinetics of the antigen-specific CD8+ T cells measured by MHC class I tetramer staining in blood. 
Data shown are mean values ± SEM (n = 18 mice/group) (B) Total MHC class I tetramer-specific CD8+ T cells induced by combinatorial MHC class I or MHC 
class I plus MHC class II SLP vaccination compared to MCMV infection at day 8 post-booster vaccination in spleen. Data represent mean values (n = 5 mice/
group). (c) The cytokine production capacity of the splenic SLP vaccine-induced CD8+ T cells was examined by intracellular cytokine staining at day 8 after 
booster vaccination. Pie charts depict the percentages of the single (IFN-γ), double (IFN-γ/TNF), and triple (IFN-γ/TNF/IL-2) cytokine producers of each 
antigen-specific CD8+ T cell populations at day 8 post-booster vaccination. (D) Phenotypic analysis of the combinatorial SLP vaccine-induced CD8+ T cells in 
spleen at day 8 post-booster vaccination. Data represent mean values (n = 5 mice/group) and are representative of three independent experiments.
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FigUre 7 | Prime-boost vaccination with a combination of Mhc class i and ii epitope-containing synthetic long peptides (slPs) exhibits 
increased potency to protect against lytic mouse cMV (McMV) infection. Unvaccinated (naive), MCMV (live-virus vaccine), combined MHC class II SLPs 
(CD4 mixture), combined MHC class I SLPs (CD8 mixture), combined MHC class I and II SLPs (CD4 + CD8 mixture), and anti-OX40 mAb only treated C57BL/6 
mice were challenged 60 days post-booster vaccination/infection with 5 × 104 PFU salivary gland-derived MCMV Smith. At day 5 post challenge, liver, lungs, 
and spleen were harvested and the viral genome copies were quantified by qPCR. To further evaluate the efficacy of the vaccines, the viral titers of chronically 
infected (MCMV chronic/day 60) mice were also measured. The viral titers of individual mice are depicted (n = 4–8 per group). Statistical significance between 
the unvaccinated group and the rest of the groups is indicated with asterisks above each group. A statistical comparison between the CD4 + CD8 mixture 
group and the MCMV (live-virus vaccine) and MCMV chronic group was also performed (vertical statistical bar). For both comparisons the statistical difference 
was found the same (**P < 0.01). The detection limit was below 1,000 genome copies as measured in naive mice. Experiment was performed twice with similar 
outcome. Statistical difference is indicated **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant as compared to the unvaccinated group unless 
otherwise indicated.
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We hypothesize that primed T cells more rapidly and stronger 
upregulated OX40 leading to greater benefit during enforced 
OX40 stimulation. OX40 ligation seems to work better on CD4+ 
T cells as compared to CD8+ T cells, which may be related to 
the higher expression of OX40 on CD4+ T cells (31, 32). Due to 
its capacity to regulate both CD4+ and CD8+ T cells, OX40 is a 
promising candidate in immunotherapy of chronic viral infec-
tions and cancer (30). In this study, we did not detect toxicity of 
OX40 agonistic antibodies but a better understanding of potential 
side-effects is required.
CD4+ T cell responses in CMV infection have been long 
known as important contributors to control primary infection 
(8, 33). In MCMV infection, CD4+ T cells direct the quality and 
persistence of inflationary CD8+ T cells and B cell responses (23, 
24, 34). Here, we show that vaccine-induced CD4+ T cells solely 
can confer moderate protection against acute MCMV infection. 
These results are consistent with other reports showing CD4+ 
T cell effectivity against MCMV and HCMV (8, 12, 25, 35–37). 
Furthermore, we observed that addition of CD4+ T cell help 
during vaccination with MHC class I SLP vaccines promoted 
priming of naïve CD8+ T cells. After booster vaccination in set-
tings wherein OX40 costimulation was enhanced, no additional 
effects of CD4 help on the magnitude and phenotype of the CD8+ 
T cells were observed, suggesting that enforced OX40 stimulation 
during booster vaccination may replace the need for CD4 help 
signals. On this basis, the improved prophylactic vaccine efficacy 
of the combined MHC class I and II SLP vaccines appears to be 
more additive rather than synergistic.
Another interesting observation was that the vaccine efficacy 
was somewhat better in liver and spleen than in lungs. A possible 
explanation for this discrepancy is that the SLP-induced CD8+ 
T cells are better capable to control the virus (lowering the viral 
titers) in the spleen and liver than the SLP-induced CD4+ T cells. 
A marked difference in the efficacy of SLP-induced CD4+ and 
CD8+ T cells as observed in liver and spleen is not found in 
the lungs and can thus be dictated by the tissue environment. 
Differences in site-specific control of MCMV-specific CD4+ and 
CD8+ T cells is known to be especially important in the salivary 
glands but for other tissues this may be important as well (33). 
Nevertheless, the combined SLP vaccines inducing both CD4+ 
and CD8+ T cell responses clearly improved the efficacy of the 
vaccine in all organ tissues. In this respect, it is of interest to 
note that SLP-based vaccines can be further refined by differ-
ent prime-booster regimens, inclusion of B cell epitopes and by 
combinations with adjuvants, immunomodulatory antibodies, 
or other vaccine platforms (38).
This study provided evidence that SLP-based vaccines 
eliciting broad CD4+ and CD8+ T cell responses can effectively 
control lytic MCMV infection without contribution by humoral 
responses. The use of OX40 as an adjuvant for MCMV peptide 
immunization strongly bolstered the development of effective 
CD4+ and CD8+ T cells. Future studies to examine the ability 
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